Compare GTIM & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTIM | KTTA |
|---|---|---|
| Founded | 1987 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 15.6M |
| IPO Year | 2013 | 2021 |
| Metric | GTIM | KTTA |
|---|---|---|
| Price | $1.28 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.2K | ★ 282.6K |
| Earning Date | 08-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.07 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $142,315,000.00 | $486,559.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.10 | ★ N/A |
| Revenue Growth | 3.01 | ★ 3130.37 |
| 52 Week Low | $1.10 | $0.28 |
| 52 Week High | $1.66 | $2.06 |
| Indicator | GTIM | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 32.31 | 33.69 |
| Support Level | $1.14 | $0.36 |
| Resistance Level | $1.34 | $0.52 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 27.27 | 14.56 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants, which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants, which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers, chicken, frozen custard; slides and drinks.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.